Drug Trial Radar · NCT02475681
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
535
Actual
Start
Jun 26, 2015
Primary completion
Feb 8, 2019
Study completion Sep 3, 2026
Sponsor
- Lead sponsor
- Acerta Pharma BVAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)
Conditions
- Chronic Lymphocytic Leukemia
Interventions
AcalabrutinibDrug
ObinutuzumabDrug
ChlorambucilDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm BTime frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Locations
155 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Goodyear, Arizona
Research Site
Phoenix, Arizona
Research Site
Anaheim, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Oxnard, California
Research Site
Palo Alto, California
Research Site
Aurora, Colorado
Research Site
Lone Tree, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
Tallahassee, Florida
Research Site
Tallahassee, Florida
Research Site
Tampa, Florida
Research Site
Niles, Illinois
Research Site
Lafayette, Indiana
Research Site
Wichita, Kansas
Research Site
Louisville, Kentucky
Research Site
New Orleans, Louisiana
Research Site
COL, Maryland
Research Site
Rochester, Minnesota
Research Site
Saint Cloud, Minnesota
Research Site
Billings, Montana
Research Site
Brick, New Jersey
Research Site
Hackensack, New Jersey
Research Site
Lake Success, New York
Research Site
New York, New York
Research Site
Blue Ash, Ohio
Research Site
Canton, Ohio
Research Site
Columbus, Ohio
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Bedford, Texas
Research Site
Dallas, Texas
Research Site
Fort Sam Houston, Texas
Research Site
Houston, Texas
Research Site
New Braunfels, Texas
Research Site
Round Rock, Texas
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.